SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. NASDAQ:SCYX (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it has been awarded a contract by the Biomedical Advanced…